» Articles » PMID: 30373114

Explorative Study on Isolation and Characterization of a G4 Bacteriophage, EMCL318, Against Multi-Drug-resistant 15-318

Overview
Specialty Pharmacology
Date 2018 Oct 31
PMID 30373114
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Bacteriophages screened and isolated from sewage water samples exhibited antibacterial activities against multi-drug-resistant strains. Five different water samples from Canadian habitats such as Kamloops Wastewater Treatment Center, Domtar, the Pacific Ocean, Bisaro Anima Cave, and alkali ponds, were used in this study. Four strains including one non-resistant and three clinical multi-drug strains ( 15-102, 15-124, and 15-318) were selected as target bacteria to screen for the bacteriophages from these collected water samples. Seeded agar assay technique was implemented for the screening. It was found that only sewage water sample exhibited a significant number of plaques count with the 15-318 (1.82 × 10² plaques/plate) cells in comparison to non-resistant strain K12 (8 plaques/plate). The phage did not produce plaques in the 15-124 and 15-102 strains. The bacteriophage, designated EMCL318, was isolated, purified, characterized, and identified to belong to the G4 species of the Family , GenBank accession number MG563770. This is an explorative study conducted in order to reveal the viruses as alternative potentials to fight against emerging and existing multi-drug-resistant infectious diseases.

Citing Articles

Synergistic action of phages and lytic proteins with antibiotics: a combination strategy to target bacteria and biofilms.

Lu H, Li Z, Elbaz A, Ni S BMC Microbiol. 2023; 23(1):149.

PMID: 37221517 PMC: 10204329. DOI: 10.1186/s12866-023-02881-2.


Taxonomic and Metabolite Diversities of Moss-Associated Actinobacteria from Thailand.

Insuk C, Pongpamorn P, Forsythe A, Matsumoto A, Omura S, Pathom-Aree W Metabolites. 2022; 12(1).

PMID: 35050144 PMC: 8777641. DOI: 10.3390/metabo12010022.

References
1.
Carlton R . Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz). 1999; 47(5):267-74. View

2.
Wommack K, Colwell R . Virioplankton: viruses in aquatic ecosystems. Microbiol Mol Biol Rev. 2000; 64(1):69-114. PMC: 98987. DOI: 10.1128/MMBR.64.1.69-114.2000. View

3.
Sulakvelidze A, Alavidze Z, Morris Jr J . Bacteriophage therapy. Antimicrob Agents Chemother. 2001; 45(3):649-59. PMC: 90351. DOI: 10.1128/AAC.45.3.649-659.2001. View

4.
Miller R . Environmental bacteriophage-host interactions: factors contribution to natural transduction. Antonie Van Leeuwenhoek. 2001; 79(2):141-7. DOI: 10.1023/a:1010278628468. View

5.
Biswas B, Adhya S, Washart P, Paul B, Trostel A, Powell B . Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun. 2001; 70(1):204-10. PMC: 127648. DOI: 10.1128/IAI.70.1.204-210.2002. View